obinutuzumab
Sign in to saveAlso known as Afutuzumab, Ro-5072759 HUMAB<CD20>, GA101, HUMABCD20, HUMAB<CD20>, RG-7159, Ro-5072759, Gazyvaro®
Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer and active lupus nephritis. It was originated by GlycArt Biotechnology AG and developed by Roche.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2013
- Admin. routes
- parenteral
- Indications
- chronic lymphocytic leukemia, non-Hodgkins lymphoma, neoplasm, lymphoma
via ChEMBL · EBI
Research
1,389 papers- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.The New England journal of medicine · 2025
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.Blood · 2025
- Obinutuzumab as treatment for ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2022
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.Lancet (London, England) · 2020
- A tale of two antibodies: obinutuzumab versus rituximab.British journal of haematology · 2018
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 5 more facts
- subject has role
- monoclonal antibody
- medical condition treated
- chronic lymphocytic leukemia
- chemical formula
- C₆₅₁₂H₁₀₀₆₀N₁₇₁₂O₂₀₂₀S₄₄
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- Chemistry
- History
- Research
- Chronic lymphocytic leukemia
- Nephropathies
- References
- External links
Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer and active lupus nephritis. It was originated by GlycArt Biotechnology AG and developed by Roche.
==Medical uses== As of 2015, obinutuzumab was being used in combination with chlorambucil as a first-line treatment for chronic lymphocytic leukemia. One more recent study has shown deeper and longer-lasting remissions through fixed-duration treatment regimens in combination with venetoclax.
Excerpted from Wikipedia’s “obinutuzumab” article, available under the CC BY-SA 4.0 licence.